Revenue Breakdown
Composition ()
No data
Revenue Streams
Anika Therapeutics Inc (ANIK) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is OEM Channel, accounting for 57.0% of total sales, equivalent to $15.84M. Another important revenue stream is Commercial Channel. Understanding this composition is critical for investors evaluating how ANIK navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Anika Therapeutics Inc maintains a gross margin of 62.65%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 2.11%, while the net margin is 5.88%. These profitability ratios, combined with a Return on Equity (ROE) of -6.71%, provide a clear picture of how effectively ANIK converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ANIK competes directly with industry leaders such as STXS and LUCD. With a market capitalization of $193.77M, it holds a leading position in the sector. When comparing efficiency, ANIK's gross margin of 62.65% stands against STXS's 50.07% and LUCD's -48.80%. Such benchmarking helps identify whether Anika Therapeutics Inc is trading at a premium or discount relative to its financial performance.
